AnaptysBio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANAB Nasdaq 2830 www.anaptysbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AnaptysBio, Inc.

AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now - May 12th, 2025 7:53 pm
Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results - May 8th, 2025 10:46 am
AnaptysBio First Quarter 2025 Earnings: Beats Expectations - May 7th, 2025 10:25 am
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates - May 5th, 2025 9:45 pm
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - May 5th, 2025 8:15 pm
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors - Apr 17th, 2025 11:00 am
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? - Mar 25th, 2025 1:21 pm
Anaptys Announces Stock Repurchase Plan - Mar 24th, 2025 1:15 pm
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - Mar 16th, 2025 10:05 am
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates - Feb 27th, 2025 11:55 pm
Anaptys Announces Participation in March Investor Conferences - Feb 27th, 2025 9:15 pm
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Feb 27th, 2025 9:15 pm
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data - Feb 13th, 2025 3:00 pm
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? - Feb 13th, 2025 2:40 pm
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? - Feb 13th, 2025 10:11 am
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial - Feb 12th, 2025 5:22 pm
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment - Feb 12th, 2025 2:23 pm
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - Feb 12th, 2025 12:30 pm
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 - Feb 11th, 2025 10:30 pm
Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago - Feb 5th, 2025 2:03 pm